Please assess the completion status of the following clinical trial:

Trial Title: EnBrace HR for Depression Treatment and Prevention in Women Trying to Conceive and Early Pregnancy

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Group 1 (Observational, not-randomized)~Inclusion Criteria:~1. Planning pregnancy or pregnant \< 28 weeks gestation~2. Currently meet criteria for stable remission from MDD, defined as a baseline score of \< 10 on the Montgomery-Åsberg Depression Rating Scale (MADRS)~3. Current or recent treatment with an AD~4. Have elected to discontinue AD medication for pregnancy (may have already begun or completed taper)~5. Have a history of a major depressive episode/ Previous Episode of MDD, as verified using the MINI Structured Clinical Interview for DSM-5; have MDD as one of their primary diagnoses~6. Has a treating prescribing clinician for the treatment of MDD~Exclusion Criteria:~1. Current major depressive episode, as diagnosed on the MINI mood portion~2. Significant risk for self-harm or harm to others~3. Psychotic symptoms~4. Meeting criteria for a primary diagnosis of schizophrenia, an active eating disorder, dementia, delirium, or other cognitive disorder~5. Presence of an active substance and/or alcohol abuse disorder within six months prior to screening~6. Pernicious anemia or history of gastric bypass surgery~7. Seizure disorder and/or on anticonvulsant medications~8. Allergy to beeswax, soy, fish, nuts, peanuts, egg, wheat, milk, and/or shellfish~9. Non-English speaking~Group 2~Inclusion Criteria:~1. Planning pregnancy or pregnant \< 28 weeks gestation~2. Currently experiencing clinically significant depressive symptoms, defined as a baseline score of \> 15 on the Montgomery-Åsberg Depression Rating Scale (MADRS)~3. Experiencing a major depressive episode, as verified using the MINI Structured Clinical Interview for DSM-5; have MDD as one of their primary diagnoses~4. Has a treating prescribing clinician for the treatment of MDD~Exclusion Criteria:~1. Significant risk for self-harm or harm to others~2. Psychotic symptoms~3. Meeting criteria for a primary diagnosis of schizophrenia, an active eating disorder, dementia, delirium, or other cognitive disorder~4. Presence of an active substance and/or alcohol abuse disorder within six months prior to screening~5. Pernicious anemia or history of gastric bypass surgery~6. Seizure disorder and/or on anticonvulsant medications~7. Allergy to beeswax, soy, fish, nuts, peanuts, egg, wheat, milk, and/or shellfish~8. Non-English speaking

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- EnBrace HR for Prevention of Depressive Relapse (Group 1) (Type: OTHER): Prescription folate prenatal supplement with other dietary ingredients; one multiphasic soft gelatin capsule 1x/day for 12 weeks. Participants are not currently in a depressive episode per the Mini International Neuropsychiatric Interview (MINI) and are not experiencing clinically significant depression symptoms assessed using the Montgomery Asberg Depression Rating Scale (MADRS) with a score \</= 10.
- EnBrace HR for Acute Treatment of Major Depression (Group 2) (Type: OTHER): Prescription folate prenatal supplement with other dietary ingredients; one multiphasic soft gelatin capsule 1x/day for 12 weeks. Participants are currently in a depressive episode per the Mini International Neuropsychiatric Interview (MINI) and are experiencing clinically significant depression symptoms assessed using the Montgomery Asberg Depression Rating Scale (MADRS) with a score \>/= 15.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete